A major stakeholder has offloaded a sizable portion of its shares in a leading pharmaceutical company. The transaction involved the sale of a 0.82% stake at an average price of Rs 5,468.99 per share, totalling a substantial Rs 541.16 crore. This bulk deal has been accepted by the pharmaceutical company, signalling a shift in its shareholder structure.
Share Price Movement
The share price of Alkem Laboratories Limited went up by 0.66 percent to Rs. 5,514 per share on Tuesday, an increase from its previous close of Rs. 5,478 per share. The market capitalisation now stands at approximately Rs. 65,267 crore as of November 26, 2024.
Bulk Deal
UBS Principal Capital Asia sold a 0.82% stake in the pharma company at an average price of Rs 5,468.99 per share, amounting to Rs 541.16 crore.
Q2 Financial Highlights
According to its recent filing, in the quarter ending September 2024, Alkem Laboratories’s consolidated revenue from operations has decreased by 0.72 percent YOY from Rs. 3,440 crore in Q2 FY24 to Rs. 3,415 crore in Q2 FY25 and increased by 12.6 percent QoQ from Rs. 3,032 crore in Q4 FY24.
The company’s consolidated net profit has increased by 14.1 percent, from Rs. 615 crore in Q2 FY24 to Rs. 702 crore in Q2 FY25. As compared to the last quarter of 2025, the company’s net profit has increased by 27.6 percent QoQ from Rs. 550 crore.
Also read…
Market Outlook
The Indian pharmaceutical industry is poised for strong growth, driven by several factors. As the third-largest pharmaceutical market by volume, India is renowned for its production of generic medicines and cost-effective vaccines. The industry boasts over 3,000 pharmaceutical companies and 10,500 manufacturing facilities approved by regulatory authorities.
Post-pandemic, there has been a notable shift in consumer mindset, leading to increased demand for vitamins, minerals, and supplements. The government’s focus on healthcare infrastructure, rising incidence of diseases, and improving health consciousness are expected to drive further market growth. The industry is projected to reach a value of US$ 163.1 billion by 2032, growing at a CAGR of 12.3%.
Shareholding Pattern
As of the November 2024 shareholding pattern, Alkem Laboratories Limited is primarily held by the promoters at 55.66 percent, domestic institutional investors hold 9.02 percent, and the public with 16.12 percent.
About Company
Alkem Laboratories, established in 1973 and headquartered in Mumbai, is a prominent pharmaceutical company in India. It specialises in the development, manufacturing, and marketing of diverse pharmaceutical and nutraceutical products. Alkem operates in over 40 countries, focusing primarily on the United States.
Alkem offers a broad range of products, including branded generics, generic drugs, APIs, and nutraceuticals. Its product portfolio spans therapeutic areas such as anti-infectives, oncology, cardiology, and neurology. The company boasts top brands like Clavam, Pan, and Taxim-O, which are widely recognised in India. Alkem operates 19 manufacturing facilities across India, ensuring high-quality production while also investing heavily in research and development, with over 500 scientists working in five global R&D centres.
In conclusion, Alkem Laboratories is a key player in the pharmaceutical industry, with a strong focus on innovation, global expansion, and sustainability. The company is well-positioned for continued success in the competitive market.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
